BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 27600563)

  • 1. Diagnosis and treatment of Paget's disease of bone : A clinical practice guideline.
    Muschitz C; Feichtinger X; Haschka J; Kocijan R
    Wien Med Wochenschr; 2017 Feb; 167(1-2):18-24. PubMed ID: 27600563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.
    Al Nofal AA; Altayar O; BenKhadra K; Qasim Agha OQ; Asi N; Nabhan M; Prokop LJ; Tebben P; Murad MH
    Osteoporos Int; 2015 Jul; 26(7):1875-91. PubMed ID: 26037791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Vidal S; Ros I; Monegal A; Bedini JL; Deulofeu R; Pons F; Muñoz-Gomez J; Ballesta AM
    Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two cases of monostotic Paget's disease: effects of bisphosphonate.
    Hoshiro M; Harada T; Iwai H; Miyatake T; Nishimura A; Ohno Y; Aoki N
    Endocr J; 2003 Aug; 50(4):385-92. PubMed ID: 14599111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
    Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
    Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paget's disease of bone: an endocrine society clinical practice guideline.
    Singer FR; Bone HG; Hosking DJ; Lyles KW; Murad MH; Reid IR; Siris ES;
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4408-22. PubMed ID: 25406796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone.
    Garnero P; Christgau S; Delmas PD
    Bone; 2001 May; 28(5):461-4. PubMed ID: 11344044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone.
    Reid IR; Maslowski K
    Calcif Tissue Int; 2017 Jul; 101(1):43-49. PubMed ID: 28324123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paget's disease of bone: presentation, extent and response to bisphosphonates.
    Wang LM; Au-Yeong ML; McKenna MJ
    Ir Med J; 2002 Sep; 95(8):244, 246. PubMed ID: 12405502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
    Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
    de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
    Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
    N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
    J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement.
    Peris P; Alvarez L; Vidal S; Kasper D; Leeming DJ; Monegal A; Angeles Martínez M; Pons F; Guañabens N
    Calcif Tissue Int; 2006 Jul; 79(1):22-6. PubMed ID: 16868670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone.
    Ohara M; Imanishi Y; Nagata Y; Ishii A; Kobayashi I; Mori K; Ito M; Miki T; Nishizawa Y; Inaba M
    J Bone Miner Metab; 2015 Sep; 33(5):584-90. PubMed ID: 25319558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone.
    Arden-Cordone M; Siris ES; Lyles KW; Knieriem A; Newton RA; Schaffer V; Zelenakas K
    Calcif Tissue Int; 1997 May; 60(5):415-8. PubMed ID: 9115157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.